Navigation Links
Experimental Drug Eases Symptoms of Mild Alzheimer's
Date:4/30/2008

Tarenflurbil lessened decline in functional ability, British study concludes

WEDNESDAY, April 30 (HealthDay News) -- Patients with mild Alzheimer's disease who took 800 milligrams of the drug tarenflurbil twice a day had less decline in functional ability than those who took a placebo, according to a British phase II trial.

The findings support phase III studies of the drug at this dose, the researchers said. Tarenflurbil reduces production of 42-amino-acid peptide, which is believed to initiate brain damage characteristic of Alzheimer's disease. Previous research had found the drug prevented learning and memory defects in mice with Alzheimer's disease.

In this study, 210 patients were randomly assigned to receive either 400 milligrams of tarenflurbil twice per day (69 patients), 800 milligrams of tarenflurbil twice per day (70 patients), or a placebo (71 patients).

Patients with mild Alzheimer's who took 800 milligrams of tarenflurbil for 24 months had lower rates of decline than those who were in the placebo group for the first 12 months of the study and either tarenflurbil group for the last 12 months of the study.

Common side effects included diarrhea, nausea and dizziness.

The researchers concluded that "800 mg tarenflurbil twice per day was well-tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild AD ... these findings justify phase III studies of tarenfurbil at the 800 mg twice daily dose in patients with mild AD."

The study was published online in The Lancet Neurology.

The findings are sufficient to support Phase III studies of the drug, Dr. Paul Aisen of the University of California, San Diego, wrote in an accompanying commentary.

"With the need so enormous, and the potential effect of the benefit suggested [although not proven] by these phase II results, the effort is indeed justified despite the substantial uncertainty. In a few months, we will learn whether tarenflurbil will be the first anti-amyloid intervention to be efficacious in a pivotal trial," Aisen wrote.

More information

The U.S. National Institute on Aging has more about Alzheimer's disease.



-- Robert Preidt



SOURCE: The Lancet, news release, April 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental Blood Substitutes Unsafe, Study Finds
2. Honda to Showcase Experimental Walking Assist Device
3. Experimental Alzheimers Drug Shows Promise
4. Experimental drug shows promise in treating certain lymphomas
5. Experimental Cancer Vaccines Show Promise
6. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
7. Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
8. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
9. 52 minority scientists receive travel fellowships to Experimental Biology 2008
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. Experimental Vaccine Halts Prostate Cancer in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers ... announced the hiring of Richard Robinson as chief operating officer (COO). In this ... with a proven track record of simplifying business processes and developing growth strategies ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... staff, and consumers are seeing lots of red these days. According to recent ... charges that result from medical coding errors(1). Some studies point to Electronic Health ...
(Date:6/25/2017)... ... ... lyric music video in Final Cut Pro X with ProLyric from Pixel Film Studios. Users ... to any song. ProLyric flies in the text for each section and it hovers around ... for optimal control. ProLyric makes editing any music video or text-based production easier than ever. ...
(Date:6/25/2017)... ... June 25, 2017 , ... With a heatwave currently bearing down on Northern California ... at the pool. Being swimsuit ready is easy with laser hair removal. , The ... can be a burdensome routine when all you want to do is get out, dive ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman ... Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency ... the dentist fit into their patients’ busy lifestyles. Dental365 also gladly work with ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC today ... Manufacturer (OEM) Board to enable seamless integration of ... monitoring systems, infusion pumps and other devices. By ... be able to help health care customers deliver ... risks related to IV therapy. "The ...
(Date:5/18/2017)... WHIPPANY, N.J. , May 18, 2017  Two ... Healthcare Businesswomen,s Association (HBA) during its recent 28 th ... New York City.  The event showcases HBA,s longstanding mission ... the business of healthcare. Cindy Powell-Steffen ... in Bayer,s U.S. Radiology division, and Libby Howe ...
Breaking Medicine Technology: